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Plasminogen activator inhibitor-1 (PAI-1) and
vitronectin are cofactors involved in pathological conditions such as injury, inflammation, and cancer, during which local levels of PAI-1 are increased and the
active serpin forms complexes with vitronectin. These
complexes become deposited into surrounding tissue
matrices, where they regulate cell adhesion and pericellular proteolysis. The mechanism for their co-localization has not been elucidated. We hypothesize that
PAI-1-vitronectin complexes form in a stepwise and
concentration-dependent fashion via 1:1 and 2:1 intermediates, with the 2:1 complex serving a key role in
assembly of higher order complexes. To test this hypothesis, sedimentation velocity experiments in the
analytical ultracentrifuge were performed to identify
different PAI-1-vitronectin complexes. Analysis of sedimentation data invoked a novel multisignal method to
discern the stoichiometry of the two proteins in the
higher-order complexes formed (Balbo, A., Minor,
K. H., Velikovsky, C. A., Mariuzza, R. A., Peterson, C. B.,
and Schuck, P. (2005) Proc. Natl. Acad. Sci. U. S. A. 102,
81– 86). Our results demonstrate that PAI-1 and
vitronectin assemble into higher order forms via a
pathway that is triggered upon saturation of the two
PAI-1-binding sites of vitronectin to form the 2:1 complex. This 2:1 PAI-1-vitronectin complex, with a sedimentation coefficient of 6.5 S, is the key intermediate
for the assembly of higher order complexes.

Plasminogen activator inhibitor type 1 (PAI-1)1 and vitronectin are biological cofactors that play a central role in extracellular matrix remodeling during pathological events such as
tissue injury and cancer progression (1–3). The serpin PAI-1 is
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the primary inhibitor of tissue- and urokinase-type plasminogen activators and thus is the main regulator of plasminmediated vascular and pericellular proteolysis (4 – 6). The circulating form of PAI-1 is found primarily in a complex with
vitronectin, with the inhibitor bound at a high affinity site
located within the amino-terminal SMB domain of vitronectin
(7–9). Vitronectin, which is found both in blood and surrounding tissues, also contains binding sites for cell surface receptors
and ECM components, both of which serve in the attachment of
cells to their surrounding matrices (10 –17).
In many instances of tissue injury, cell invasion, or tumor
development, PAI-1 and vitronectin are co-localized to the areas of vascular damage, necrosis, angiogenesis, and inflammation (2, 18 –23). In contrast to PAI-1, which is locally produced
and secreted by cells into the pericellular environment, the
main source of vitronectin for tissue deposition is probably its
recruitment from circulation. Incorporation of vitronectin into
tissue ECM is linked to “activation” of the protein into an
altered, adhesive form, which is both structurally and functionally distinct from its native, plasma counterpart (3). Adhesive
functions adopted by this altered form of vitronectin work in
parallel with the inhibitory functions of PAI-1, in a fashion that
allows for co-regulation of cell adhesion and tissue degradation.
The exact mechanism by which plasma vitronectin adopts the
altered form, is relocalized, and becomes associated with PAI-1
in tissues under pathological scenarios is currently undefined.
Interaction of PAI-1 and vitronectin affects the structural
and functional properties of both proteins. The active structure
of free PAI-1 is relatively unstable, and it readily converts into
a latent, inactive form by spontaneous insertion of its reactive
center loop into the central ␤-sheet core of the protein (24).
However, vitronectin bound to PAI-1 stabilizes the serpin in an
active, inhibitory conformation (7) by binding across the base of
the central ␤-sheet of PAI-1 and constraining the movement
necessary to accommodate insertion of the reactive center loop
(25). In addition to this stabilization, association with vitronectin endows PAI-1 with inhibitory properties toward a wider
repertoire of serine proteases, including thrombin and activated protein C, thus expanding the antiproteolytic potential of
PAI-1 (26 –28).
Binding of PAI-1 also affects the adhesive properties of
vitronectin that arise from its association with cell surfaces and
the ECM. Cell surface receptors (e.g. integrins and urokinasetype plasminogen activator receptor) bind vitronectin at sites
that lie proximal to the high affinity PAI-1 site in the SMB
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domain of vitronectin (8, 9, 29 –31). Under some conditions,
PAI-1 disrupts cell receptor binding to vitronectin via a presumed steric effect (32, 33). However, under other conditions,
PAI-1 actually promotes the association of native vitronectin
with purified integrins ␣V␤3 and GPIIbIIIa (34) or cultured
cells (34).2 In addition to such variable effects on interactions
with receptors, PAI-1 binding also enhances interactions of
vitronectin with heparin, osteonectin, and purified ECM from
human placenta (34 –36). A similar effect of PAI-1 is apparent
in cell culture, in which the PAI-1-vitronectin complexes preferentially are relocalized to the ECM of cultured fibroblasts in
a manner that requires glycosaminoglycans.2 These findings
suggest that the changes that accompany vitronectin binding
may define a mechanism for the recruitment of PAI-1 and
vitronectin to tissues in pathological situations.
Sedimentation equilibrium analysis first showed that PAI-1
interacts with vitronectin to form a complex with a 2:1 (PAI-1/
vitronectin) stoichiometry that associates into a higher order
form comprising four PAI-1 molecules and two vitronectin molecules (37). Formation of the 4:2 complex was postulated to
proceed via transient 1:1 and 2:1 species, although these intermediates were not significantly populated in the equilibrium
studies (37). This study provided the first evidence that PAI-1
binds simultaneously to two sites on vitronectin and prompted
our working hypothesis, that formation of these 2:1 complexes
is the step that controls the pathway for assembly of higherorder PAI-1-vitronectin complexes that adopt altered adhesive
properties. In the present study, hydrodynamic approaches
were expanded to investigate the mechanism of assembly with
defined intermediates to produce multivalent, higher order
complexes containing PAI-1 and vitronectin.
MATERIALS AND METHODS

Purification and Labeling of Vitronectin—Monomeric vitronectin
was purified from human plasma as described previously (38, 39). For
multiwavelength studies, vitronectin was labeled with fluorescein isothiocyanate using a FluoReporter® protein labeling kit (Molecular
Probes, Inc., Eugene, OR) that labels primary amines. The molar ratio
of dye to vitronectin in the labeling reaction typically resulted in conjugation of ⬃2 fluorescein molecules per vitronectin monomer; labeling
ratios varied from 1.5 to 1.8 mol of fluorescein per mol of vitronectin.
The labeled vitronectin monomer was fully functional, with no adverse
effects of labeling on PAI-1 binding.
Mutagenesis, Expression, and Purification of Recombinant PAI-1—
The stable I4 –1B mutant PAI-1 (40) and latent PAI-1 were obtained
from Molecular Innovations, Inc. The W175F variant (41) and PAI-1R
(PAI-1 containing two amino acid replacements, T333R and A335R (42))
were produced as described (in Refs. 41 and 42, respectively). The
recombinant human PAI-1 gene was cloned into the pET-24d vector
(Novagen) as described previously (43). The M347C (P1⬘-Cys) form of
PAI-1 was engineered by site-directed mutagenesis using the MutaGene phagemid in vitro mutagenesis kit (Bio-Rad) using the mutagenic
oligonucleotide 5⬘-1125dGATCTCCTCGGGGGCACAGCGGGCTGAGACTAT1093-3⬘. All mutations were confirmed by DNA sequencing of the
full-length PAI-1 gene.
Mutant and wild-type PAI-1 constructs were expressed in the Escherichia coli strain BL21(DE3)pLysS and purified as described (43).
Labeling of the P1⬘-Cys PAI-1 variant with 5-iodoacetamidofluorescein
(Molecular Probes) was carried out as described previously (44) with a
labeling efficiency of 1–1.2 mol of 5-iodoacetamidofluorescein/mol of
PAI-1 variant. Latent PAI-1 that typically accumulated during the
labeling reaction was removed by affinity chromatography on immobilized ␤-anhydrotrypsin as described (41). All final unlabeled and P1⬘fluorescein-labeled preparations were shown to be ⬎98% active by
detecting a stable, inactive acyl-enzyme complex with tPA using SDSPAGE analysis (41, 43). PAI-1 protein concentrations were determined
from absorption at 280 nm, using a Mr of 43,000 and extinction coefficients of 0.93 ml mg⫺1 cm⫺1 for wild-type PAI-1 (45) or 0.83 ml mg⫺1
cm⫺1 for W175F PAI-1 (41). Concentrations of labeled P1⬘-fluorescein

PAI-1 were determined by the Bradford dye-binding assay (Bio-Rad)
using wild-type PAI-1 as the standard (46).
Kinetic Assay to Quantify Active PAI-1—Equimolar amounts of PAI-1
and vitronectin (2 M) were mixed in phosphate-buffered saline (10 mM
dibasic sodium phosphate, 2 mM monobasic potassium phosphate, pH
7.4, containing 0.14 M NaCl and 3 mM KCl) and incubated at room
temperature. At various time points from 15 min to 35 h, an aliquot of
the vitronectin/PAI-1 mixture was added to 2 M tPA and incubated at
37 °C for 10 min to allow inactivation of tPA by active PAI-1. The
vitronectin/PAI-1/tPA mixture was added to 0.1 mM Spectrozyme® tPA
(American Diagnostica Inc., Stamford, CT), and the absorbance at 405
nm was read after 5 min.
Sedimentation Velocity Experiments—A Beckman Optima XL-I analytical ultracentrifuge equipped with both absorbance and interference
optical detection systems were used to follow the formation of higher
order complexes between vitronectin and PAI-1. Epon double sector
centerpieces were filled with 400 l of samples containing either
vitronectin or PAI-1 alone or mixtures of the two at varying molar
ratios. All samples were first dialyzed extensively against phosphatebuffered saline. For all experiments, the dialysate was loaded into the
reference sector. Samples were centrifuged at a rotor speed of 50,000
rpm, and data were collected in fringes using interference optics and/or
by absorbance at 494 nm, the extinction maximum for fluorescein.
Hydrodynamic Modeling of the Sedimentation Velocity Data—Sedimentation velocity analyses were performed with the program SEDFIT
(available on the World Wide Web from www.AnalyticalUltracentrifugation.com) as described in detail in Ref. 47 that carry out size distribution analyses based on Lamm equation modeling (48 –50). Briefly, the
analysis of velocity profiles was performed by direct boundary modeling
by distributions of Lamm equation solutions c(s) with the following,
smax

a(r,t) ⬵

冕

c(s)1(s,F,r,t)ds ⫹ b(r) ⫹ ␤(t)

(Eq. 1)
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where a(r,t) denotes the measured absorbance or interference profiles
at position r at time t, b(r) and ␤(t) are the characteristic systematic
offsets (50), and 1(s,F,r,t) are solutions of the Lamm equation,
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(with  denoting the rotor angular velocity, D the diffusion coefficient,
and s the sedimentation coefficient) at unit loading concentration (51).
D and s are related via the frictional ratio F ⫽ (f/f0) and the hydrodynamic scale relationship,
D(s) ⫽

冑2 ⫺1/2
kTs
(F)⫺3/2 ((1 ⫺ v )/v )1/2
18

(Eq. 3)

(with  and  the solvent viscosity and density, respectively, and  the
partial specific volume of the macromolecules, which were calculated
using the software SEDNTERP (50)). The nonlinear regression with
Equation 1 was combined with the determination of the best fit weight
average frictional ratio, the best fit meniscus position, and the algebraic
calculation of systematic time-invariant and radial-invariant noise
components and maximum entropy regularization at a confidence level
of 0.70 (47, 51). Because these systematic signals are arbitrary offsets
introduced from the detection system, calculated systematic offsets can
be subtracted from the raw data without introduction of bias if the
degrees of freedom in the analysis are not reduced. Therefore, the final
calculated best fit offsets are subtracted from the raw data for presentation purposes. In all calculations, both meniscus and frictional ratio
parameters were optimized by carrying out nonlinear regression to
obtain best fits. s values were converted to standard conditions in water
at 20 °C with the program SEDNTERP (50).
Multisignal Analysis of Sedimentation Data for Fluorescently Labeled PAI-1/Vitronectin Mixtures—Sedimentation velocity data acquired simultaneously at different signals (refractive index and absorbance) were globally modeled with a superposition of component
sedimentation coefficients ck(s) according to the following,
smax
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where ⑀k denotes the extinction coefficient (or generalized signal increment) of component k at signal . This multisignal generalization of
Equation 1 for heterogeneous protein interactions is described in detail
elsewhere (52) and was implemented in the software SEDPHAT (available on the World Wide Web at www.AnalyticalUltracentrifugation.com). Briefly, the extinction coefficients were predetermined in
separate experiments with each protein component alone. As a result,
the global modeling of data acquired at different wavelengths (or signals) permits a spectral distinction of the different sedimenting protein
components and allows for separate deconvolution of the sedimentation
coefficient distributions ck(s) of species containing protein component k.
Although this may lead also to slightly enhanced deconvolution of the
hydrodynamic separation, it has properties very similar to those of the
c(s) with regard to the influence of reaction kinetics on the obtained
sedimentation coefficient distributions (48). Reactions that are fast on
the time scale of sedimentation can be diagnosed by concentration-dependent peak positions in ck(s), which reflect the characteristic s values
of the reacting system, but with different ck(s) still reflecting the correct
stoichiometry (52). Like c(s) (48, 50, 53), reactions that are slow on the
time scale of sedimentation, such as those studied in the present communication, result in peak positions of ck(s) that correspond to different
sedimenting species.
RESULTS

Characterization of PAI-1 and Vitronectin—The design of
this study is to use hydrodynamic methods to critically evaluate the formation of PAI-1-vitronectin complexes. The SV
method, which provides first principle hydrodynamic information concerning the size, shape, and stoichiometries of macromolecules in heterogeneous populations of interacting species,
was adopted to characterize all complexes that form upon
PAI-1 binding to vitronectin.
As a first step in the analysis, experiments were conducted to
characterize the hydrodynamic properties of the individual proteins. Fig. 1 shows the sedimentation profiles for PAI-1 and
vitronectin (Fig. 1, A and B, respectively) and the sedimentation coefficient distributions c(s) for both PAI-1 and vitronectin
obtained from these analyses (Fig. 1C). For both samples, a
major species is apparent, with peak s values centered at 3.4
and 4.2 S for PAI-1 and vitronectin, respectively (Table I). This
observation was made essentially independent of protein concentration. The small peak at a higher s value of 6.2 S corresponds to a small amount of vitronectin dimer that appears to
a variable extent in purified vitronectin samples (7). The quality of fit was high, with root mean square deviations in both
cases on the order of instrument noise. The observed s values
are consistent with the monomeric state of the proteins, as
summarized in Table I, which lists theoretical s values for
spherical proteins of this size for comparison. The best fit
frictional ratios (f/f0) were 1.2 for PAI-1 and 1.5 for vitronectin
(Table I). This indicates a small degree of shape asymmetry for
PAI-1, which is compatible with the dimensions of the protein
known from crystallography (54). For vitronectin, the series of
SV experiments gave consistently a frictional ratio of 1.5–1.7,
indicating that the protein is significantly asymmetric. This is
supported by recent data using small angle x-ray scattering on
the native vitronectin monomer that indicate that the shape of
the molecule deviates significantly from that of a sphere, yielding a bilobed shape with a maximal linear dimension of 110 Å
and average hydrodynamic radius of ⬃30 Å (55).
Mixtures of PAI-1 and Vitronectin Form Reversible Higher
Order Complexes—With the goal of examining the mechanism
of assembly of PAI-1-vitronectin complexes, SV experiments
were conducted on mixtures of the two proteins under varying
conditions. As previously described (34), the complexes formed
can be observed in size exclusion chromatography and therefore dissociate slowly relative to the time scale of the SV data
acquisition. In other words, the dissociation constants of the
complexes reflect rapid association and slow dissociation rates.
As a consequence, the peaks observed in c(s) analysis reflect the

FIG. 1. Sedimentation velocity analysis of PAI-1 and vitronectin using SEDFIT. PAI-1 (3.5 M) and vitronectin (3.5 M) were
analyzed individually by centrifugation at 50,000 rpm at 22 °C in a
Beckman-Coulter XLI analytical ultracentrifuge, and sedimentation
was monitored by interference detection. SV data were analyzed using
a continuous c(s) distribution model implemented in the program SEDFIT. Partial specific volumes calculated on the basis of amino acid and
carbohydrate content for recombinant PAI-1 and human vitronectin
were 0.74 and 0.705 ml䡠g⫺1 (Table I). The frictional ratio for each
sample was a fitted parameter in the analysis. Representative sedimentation data, with global fits to each data set, are shown for PAI-1 and
vitronectin in A and B, respectively, and resulting residuals for each
analysis are given below each SV data profile. Scans were collected at
approximate 11-min intervals. All data were included in the calculations of c(s) distributions. c(s) distribution profiles for the two proteins
are shown in C (black line, PAI-1; blue line, vitronectin).

sedimentation rates of the different species formed stably during the time frame of individual SV experiments (48, 50, 53).
Representative SV data on the PAI-1/vitronectin mixture are
shown in Fig. 2A. From the SV data acquired on an equimolar
8 M mixture of vitronectin and PAI-1, three major peaks at s
values of 6.5, 8.6, and 10.9 S, respectively, were resolved in
addition to several higher order complexes ranging from ⬃12 to
25 S (Fig. 2B). Consistent with previous studies (34, 35, 37), the
hydrodynamic profiles show that PAI-1 binds to vitronectin
and results in the formation of a variety of complexes, including
multiple higher order oligomers.
To test the reversibility in assembly of these higher order
complexes, the equimolar 8 M PAI-1/vitronectin mixture was
diluted to varying concentrations that were analyzed by SV
(Fig. 2, C and D). The results demonstrate that dilution over a
concentration range from 8 to 1.6 M significantly alters the
c(s) distribution profiles of the PAI-1/vitronectin mixtures. As
summarized in Table I, the 1–5, 5.1–7.4, and 7.5–25 S intervals
of sedimentation coefficients are hydrodynamically consistent
with free vitronectin and/or PAI-1, intermediate 1:1 and 2:1
PAI-1-vitronectin complexes, and higher order complexes, respectively. To quantify changes observed in Fig. 2, B–D, peaks
within these three different ranges of s values were integrated
to obtain total amounts of the corresponding species (Table II).
Only the distribution of PAI-1-vitronectin complexes, characterized by sedimentation coefficients above 5 S, is shown in
Fig. 2. For each of the protein concentrations tested, the pro-
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TABLE I
Sedimentation coefficients for PAI-1, vitronectin, and PAI-1-vitronectin complexes

a
The molecular weight of PAI-1 was calculated from its amino acid sequence. The molecular weight of vitronectin originally determined by
equilibrium analytical ultracentrifugation (35) was recalculated as 62,000 using a corrected v that includes contributions of carbohydrate side
chains (53).
b
Partial specific volumes were calculated using SEDNTERP from the known sequences of PAI-1 and vitronectin. The partial specific volume of
vitronectin also included the contribution from an average of two biantennary and one triantennary carbohydrate side chain per molecule, with
an average sequence as reported (77).
c
A partial specific volume typical for protein samples was used in calculations for complexes of PAI-1 and vitronectin.
d
Maximum sedimentation coefficients for a spherical, nonhydrated molecule calculated from the molecular weights using SEDFIT.
e
Range in sedimentation coefficients observed under experimental conditions.
f
Sedimentation coefficients converted to standard conditions of 20 °C in water ⫾ S.D. (n ⫽ 4). s20w values were calculated using the SEDNTERP
and SEDPHAT programs.

portion of signal corresponding to s-values between 1 and 5 S,
representing free PAI-1 and/or vitronectin, consistently was
⬃30% of the total signal (not shown), consistent with our prior
sedimentation equilibrium studies on 1:1 mixtures of the two
proteins (37). The 5.1–7.4 and 7.5–25 S integration ranges,
corresponding to intermediate and higher order complexes,
respectively, are indicated by colored bars at the top of Fig. 2B.
What is most significant about the findings is the apparent
reversibility of formation of higher order complexes with s
values between 7.5 and 25 S, with a concomitant emergence of
intermediate complexes in the 5.1–7.4 S range. As demonstrated in Fig. 2D, with an equimolar concentration of PAI-1
and vitronectin at 1.6 M, only 6% of the total reaction mixture
is present in the higher order complexes with s values above 7.5
S. This contrasts with the mixtures containing the 8 and 3.2 M
concentrations, which showed complexes in this range equal to
50 and 30% of the total mass, respectively (Table II).
The decrease in the abundance of sedimenting species with s
values greater than 7.5 S in the more diluted mixtures is
mirrored by the accumulation of intermediate species at ⬃6 S.
For example, in the 1.6 M equimolar mixture, with only 6% of
the total mass sedimenting as higher order species, a full 64%
of the total mass loaded corresponds to species in the intermediate s range of 5.1–7.4 S. A similar distribution of species was
observed when the mixture of PAI-1/vitronectin was further
diluted to ⬃400 nM, approaching the detection limit of the
analytical ultracentrifuge (data not shown). When comparing
the samples measured at the highest concentration to more
dilute samples, peaks in the c(s) distribution at intermediate
sedimentation values from 5.1 to 7.4 S vary in peak width and
position. For example, the species observed at ⬃6.5 S in the 8
M equimolar mixture shifts to a broader peak with a maximum near ⬃6 S at lower protein concentrations tested. As
discussed below, this sedimentation coefficient of ⬃6 S represents a mixture of 1:1 and 2:1 PAI-1-vitronectin complexes that

are not resolved in this experiment. Because of the apparent
interdependence of species with intermediate (5.1–7.4 S) and
high (7.5–25 S) sedimentation coefficients, we focused on characterizing the composition of the intermediate species in further experiments.
Formation of Higher Order Complexes Occurs in a Concentration-dependent Fashion—To test the concentration dependence of the assembly of oligomeric complexes, SV analysis was
performed on mixtures where one of the proteins was held
constant while the other was varied. For one set of experiments
(Fig. 3A), vitronectin was maintained at a constant concentration of 1.6 M. This particular vitronectin concentration leads
to the assembly of a predominant species in the intermediate
range with a sedimentation coefficient near 6 S (Fig. 2). Furthermore, this concentration is physiologically relevant and
reflects the levels of vitronectin found in normal circulation
(56 –58). As shown in Fig. 3A, increases in the molar concentration of PAI-1 relative to vitronectin alter the c(s) distributions, with several higher order complexes that form at high
concentrations of PAI-1.
A clearer picture of this dose dependence is seen in Fig. 3B,
which focuses more closely on species distributed between 4.5
and 15 S. A substoichiometric molar ratio of PAI-1 to vitronectin (1:4) results in the assembly of complexes primarily distributed between ⬃5 and 7 S. When PAI-1 is mixed with vitronectin at equimolar levels, a significant increase in complexes in
this range is evident. Moreover, the partial resolution of the
broad peak between 5 and 7 S into a peak at ⬃5.5 S and a
shoulder at 6.5 S is noteworthy. These species appear to represent PAI-1-vitronectin complexes with molar stoichiometries
of 1:1 and 2:1, respectively (Table I; see below). Also, some
higher order species with s values greater than 7 S emerge in
this mixture. A further increase in PAI-1 concentration to a
molar ratio of 4:1 results in further redistribution of sedimenting species that is quite dramatic. First, the broad peak be-
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FIG. 2. c(s) distribution analysis of mixtures of PAI-1 and
vitronectin. Equimolar amounts of PAI-1 and vitronectin were mixed
for 1 h and were analyzed by SV at 50,000 rpm at 25 °C. Representative
data collected using interference optics are shown in A. These data were
fit using the continuous c(s) distribution model in SEDFIT, and the fit
to the data for an 8 M PAI-1/vitronectin mixture is given by the solid
lines in A, with residuals for the fit shown below the data. Scans
collected at different time intervals are shown in different colors for
clarity, and only a subset (every other scan) of the interference data is
shown. Scans were collected at approximate 1-min intervals. Resulting
c(s) distributions for a dilution series originating from the 8 M PAI-1/
vitronectin mixture are shown in B (8 M mixture), C (3.2 M mixture),
and D (1.6 M mixture). A range of s values from 5 to 25 S is plotted in
B–D, corresponding only to intermediate (5.1–7.4 S) and higher order
(⬎7.5 S) PAI-1-vitronectin complexes. These ranges in s values, corresponding to the integration ranges in Table I, are denoted, respectively,
by the red and blue bars above B. Species with s values of ⬍5 S,
corresponding to free vitronectin and/or PAI-1 and quantified in Table
I, are not shown.

comes more resolved with a predominant peak at ⬃6.5 S and a
corresponding decrease in the ⬃5.5 S complex. Thus, the 2:1
PAI-1-vitronectin complex is favored at higher PAI-1 concentrations. Second, at this point, there is an accumulation of
significant levels of higher order species with s values greater
than 7 S. Multiple higher order complexes are present, including those at s values of 8.7, 12.9, 16.4, 20.7 S, and greater.
Thus, it appears that appreciable formation of these higher
order complexes is only seen when the intermediate 6.5 S
complex is populated.
A converse experiment also was performed in which the
PAI-1 concentration was fixed and vitronectin was varied. As
shown in Fig. 3C, accumulation of PAI-1-vitronectin complexes
depends on the relative abundance of the two proteins. The
results of this experiment are similar to those in Fig. 3A, in
which higher protein concentrations lead to the population of a
6.5 S complex and a concomitant generation of higher order
complexes. Although the formation of higher order complexes
at the highest protein concentrations is apparent, the abun-
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dance of these complexes relative to total protein is less than
observed at the highest protein concentrations measured in
Fig. 3A. This is an expected result, since the highest protein
concentrations in Fig. 3C correspond to excess vitronectin (i.e.
experimental conditions that favor primarily the occupation of
the high affinity PAI-1-binding site rather than the second,
lower affinity site on vitronectin). As a result, there is less
accumulation of the 6.5 S (2:1) intermediate and pursuant
higher order species compared with the highest protein concentrations in Fig. 3A in which PAI-1 is in excess and both binding
sites on vitronectin are occupied. The analyses of varying protein ratios in Fig. 3 support a mechanism for the accumulation
of higher order species (⬎7.5 S) via formation of the 6.5 S
species as an intermediate.
Multisignal Sedimentation Velocity Analysis Confirms the
Binding of Two PAI-1 Molecules to Vitronectin—What is this
critical complex that sediments with an s value of 6.5 S? Our
hypothesis is that it is a 2:1 complex with two molecules of
PAI-1 bound to distinct sites on a single molecule of vitronectin
(Table I). We suggest that these two sites on vitronectin differ
in affinity, with the high affinity site (Kd ⬃ 1–10 nM (29, 59))
resident in the SMB domain and a second lower affinity site (Kd
⬃ 25–50 nM (34)3) located outside the SMB region at a yet
unidentified locus. Because of the differences in affinity, these
binding sites should be occupied in a concentration-dependent
fashion, and our SV results support this notion. Furthermore,
we hypothesize that it is the saturation of both binding sites
that forms the crucial 2:1 complex that then serves as a physiological “trigger” to induce the formation of higher order PAI1-vitronectin complexes. To test this hypothesis, a definitive
identification of the composition and stoichiometry of this 6.5 S
complex is needed.
For this purpose, we have used a new multiwavelength approach that allows simultaneous analysis of each protein in the
complex (52). We have performed a global analysis of multisignal SV data for unraveling the populations and stoichiometries
of heterogeneous protein complexes formed between PAI-1 and
vitronectin. We have focused our attention primarily on the
species identified at ⬃6.5 S. Multiwavelength analysis has
been used fruitfully with this system of interacting proteins in
our prior sedimentation equilibrium measurements (37), taking advantage of different absorbance properties for proteins
selectively labeled with chromophores. In a similar strategy,
the SV analysis was carried out using labeled PAI-1 and/or
labeled vitronectin by collecting absorption and interference
optical data from the same cell.
The analysis was implemented in the program SEDPHAT,
for which features are described in detail elsewhere (52). From
a global multisignal analysis, the new method permits a direct
calculation of the separate c(s) distributions of the different
protein components, termed ck(s), based on the predetermined
contributions of each protein to all of the observed signals (52).
The analysis shown in Fig. 4 was performed on data acquired
using fluorescein-labeled vitronectin and unlabeled PAI-1 (Fig.
4, A and B, interference and absorbance data, respectively).
Both sets of data were globally fit by the multisignal/wavelength analysis approach using experimentally determined values representing both chromophoric and interference-coupled
extinction coefficients. Analyses resulted in well fit data for the
experiments, with both local and global errors in the acceptable
range, as shown in the residuals shown below the data. Similar
results were obtained from the analysis using the opposite
labeling strategy with fluorescein-labeled PAI-1 and unlabeled
vitronectin (data not shown).

3

C. S. Schar and C. B. Peterson, unpublished data.
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TABLE II
Assembly of vitronectin and PAI-1 into intermediate and higher order complexes
Ranges in s values were defined for integration according to the criteria outlined in Table I, with species sedimenting with s values in the range
from 1 to 5 S representing free vitronectin and PAI-1, species with s values in the range from 5.1 to 7.4 S representing intermediate 1:1 and 2:1
complexes, and species sedimenting with s values greater than 7.5 S representing higher order complexes of vitronectin and PAI-1.
Protein samples

Vitronectin
Vitronectin
Vitronectin
Vitronectin
Vitronectin

⫹
⫹
⫹
⫹
⫹

wild-type PAI-1
wild-type PAI-1
wild-type PAI-1
Y175F PAI-1
PAI-1R

Protein concentrations

8 M vitronectin 8 M
3.2 M vitronectin 3.2
1.6 M vitronectin 1.6
3.3 M vitronectin 3.3
3.3 M vitronectin 3.3

PAI-1b
M PAI-1b
M PAI-1b
M PAI-1
M PAI-1

Unbound proteins
(fraction in s range from
1 to 5 S)a

Intermediate complexes
(fraction in s range from
5.1 to 7.4 S)a

Higher order complexes
(fraction in s range from
7.5 to 25 S)a

%

%

%

26
25
30
25
20

24
45
64
34
40

50
30
6
41
40

a
Sedimentation data were evaluated as c(s) profiles, and data were integrated using SEDFIT to determine the relative amounts of various
PAI-1-vitronectin complexes formed in the three mixtures. Values were normalized by dividing the integrated values by the total loading signal
in fringes and multiplying by 100 to obtain a percentage of the various species formed. Errors are ⫾ 5%.
b
c(s) distributions of complexes with s values ⬎5 S for the three concentrations of vitronectin and wild-type PAI-1 samples are shown in Fig. 3,
B–D. Free proteins that sediment in the 1–5 S range are not shown in the figure, but the integrations over this s range are shown here.

FIG. 3. SV analysis to evaluate the concentration dependence
of formation of higher order PAI-1-vitronectin complexes. PAI-1
and vitronectin were mixed under conditions where the concentration of
one protein was held constant while the other was varied. The proteins
were mixed for 1 h and were analyzed by SV at 50,000 rpm at 20 °C with
detection by interference optics. Data were analyzed using SEDFIT. A
and B show c(s) distributions for mixtures of 1.6 M vitronectin with 0.4
M PAI-1 (black line), 1.6 M PAI-1 (blue line), or 5.6 M PAI-1 (red
line). B gives an expanded view of the c(s) distribution between s values
of 4.5–15 S. An asterisk denotes the critical 6.5 S complex. C shows the
converse titration in which PAI-1 was held constant at 3.5 M, and the
vitronectin concentration was varied between 0.87 M (black line), 1.7
M (blue line), and 7 M (red line).

The analysis of the mixture using fluorescein-labeled
vitronectin and unlabeled PAI-1 shows both protein components in co-sedimenting peaks, as expected, since they form
complexes (Fig. 4C). The relative amounts of signal indicate
that the complex with a sedimentation coefficient of ⬃6.5 S
contains a molar excess of PAI-1, and integration of the peak
areas in this c(s) distribution shows that this 6.5 S complex
contains a molar ratio of 2:1 PAI-1/vitronectin. The calculation
of this molar ratio relies on the relative heights of the boundaries of the sedimenting components detected using the two
signals from interference and absorbance optics. Thus, the
multiwavelength approach explicitly identifies the 2:1 intermediate that is required for assembly to higher order species. Also,
the higher order species that exhibits a sedimentation coeffi-

FIG. 4. Global multisignal analysis demonstrates the formation of a 2:1 PAI-1-vitronectin complex at 6.5 S. Solutions of
either fluorescein-labeled PAI-1 (8 M) or fluorescein-labeled
vitronectin (2 M), mixed for 1 h with the corresponding nonlabeled
protein, were analyzed by sedimentation velocity at 50,000 rpm at
20 °C. For each mixture, both interference and absorbance at 494 nm
were collected. Interference and absorbance scans were taken every 4
min. Resulting profiles were analyzed using a novel multisignal analysis feature implemented in the program SEDPHAT. Prior experiments were carried out to determine the chromophoric and interference-coupled extinction coefficients, which were included in the
analysis of mixtures. SV data, with fits to each data set, are shown for
the mixture of fluorescein-labeled vitronectin with unlabeled PAI-1 in
A (interference data) and B (absorbance data at 494 nm). Vertical
green lines in panels A and B represent the boundaries on data
included in the global fits. Resulting residuals for each analysis are
given below each SV data set. A representative multisignal c(s) analysis is shown in C, with the distribution of PAI-1 and vitronectin
represented by red and blue lines, respectively.
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cient of ⬃8 S (Fig. 4C) contains the same molar stoichiometry
of vitronectin and PAI-1, identifying this species as the 4:2
complex (Table I). The same approach applied to other higher
order complexes was less definitive (mainly due to their limited
abundance and small contribution in the visible absorbance
signal) but clearly indicated the presence of molar excesses of
PAI-1 in several cases (data not shown).
A detailed interpretation of the peak shapes from this multiwavelength analysis is not possible currently, due to probable
effects of the signal/noise ratio on the degree of regularization
in the calculated curves and the potential influence of slight
mismatches in the meniscus position of the different data sets.
It should be noted that in theory the component ck(s) distributions of interacting species cannot necessarily be expected to be
in perfect register, due to the effects of finite reaction kinetics4
and the dispersion of composition in the reaction boundary
predicted by Gilbert-Jenkins theory (60), which can apply to
c(s) distributions.5 Despite these effects, the integral over the
peaks of the reaction boundary reports the stoichiometry of the
complexes. Thus, the multisignal analysis provides conclusive
evidence that PAI-1 and vitronectin interact to form a 2:1
complex that sediments at ⬃6.5 S, supporting our hypothesis
that formation of a 2:1 PAI-1-vitronectin complex serves as a
building block in the formation of higher order oligomers.
Oligomeric Forms of Vitronectin Persist at Long Incubation
Times—PAI-1 is a unique member of the serpin family that
spontaneously converts over time to a latent, noninhibitory
conformation (61, 62). This conformational change in PAI-1
also renders the protein incapable of binding to vitronectin
(63). To evaluate the effects of this transition to latent PAI-1 on
the distributions of higher order complexes, a time course was
evaluated over ⬎24 h. In these experiments, equimolar mixtures of PAI-1 and vitronectin were incubated at room temperature for different time intervals and then subjected to SV
analysis. As shown in Fig. 5A, c(s) distributions for mixtures
incubated at 1 and 6 h are similar, with a nearly equivalent
population of the species at ⬃6.5 S. However, there is a redistribution of higher order species with s values greater than 7.5
S, most apparent for the species with a sedimentation coefficient ⬃8 S (Table I). It is probable that this redistribution
reflects an accumulation of higher order forms that assemble
on a longer time scale than the 2:1 intermediate at ⬃6.5 S.
As incubation times are increased to 12 and 24 h, there is
further redistribution, with a time-dependent loss of higher
order species. These changes are attributed to dissociation of
the complexes as PAI-1 is converted to the latent form that does
not bind to vitronectin (37). Consistently, the time-dependent
loss of higher order species correlates well with the rate at
which PAI-1 converts to a latent form under these conditions
(Fig. 5B). Also consistent is the loss over time of the ⬃6.5 S (2:1)
intermediate, coincident with the accumulation of significant
amounts of free vitronectin and latent PAI-1. In agreement
with previous work (34, 35), some oligomeric forms of vitronectin persist even at the longest times that correlate with complete loss of active PAI-1. Indeed, almost 44% of the total
loading signal for vitronectin was still present as oligomers
after 24 h.
Assembly of PAI-1-Vitronectin Complexes Is Independent of
the Anti-protease Activity of the Inhibitor—Is the spontaneous
conversion of PAI-1 to a latent conformation required for accumulation of vitronectin oligomers that persist at long times, as
shown in Fig. 5? Must PAI-1 be active as a protease inhibitor to
be effective in promoting the formation of higher order com4
Dam, J., Velikovsky, C. A., Mariuzza, R. A., Urbanke, C., and
Schuck, P. (2005) Biophys. J., in press.
5
Dam, J., and Schuck, P. (2005) Biophys. J., in press.
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FIG. 5. Test for the presence of vitronectin oligomers as a
function of time. PAI-1 and vitronectin were mixed at equimolar
concentrations of 3.3 M and incubated at room temperature for various
amounts of time and then analyzed by SV at 50,000 rpm at 25 °C using
interference optics. Distributions at 1 h (blue line), 6 h (red line), 12 h
(green line), and 24 h (black line) time points are shown in A. Over this
same time course up to 35 h, the ability of PAI-1 in the mixture to
inhibit tPA was measured to monitor the conversion of PAI-1 to the
inactive, latent form. The results of these kinetic assays are shown in B.

plexes? To address such questions, mutant forms of PAI-1 were
used that exhibited either slower rates of conversion to the
latent form (40, 41) or impaired anti-protease activity (42).
Several forms of PAI-1 have been engineered by introduction of
strategic mutations that disfavor conversion to a latent structure and thus allow PAI-1 to retain activity for a long period
of time.
Analysis of a stable form of PAI-1, the W175F mutant (41),
gave a common c(s) distribution pattern of PAI-1-vitronectin
complexes induced by W175F versus wild-type PAI-1, with the
distribution of species in the 1–5, 5.1–7.4, and ⬎7.5 S ranges
summarized in Table II. It is clear from the results on this
“stable” mutant that the inherent rate of conversion to a latent
form is not a critical feature that determines the ability of
PAI-1 to form higher order complexes with vitronectin. Consistent with previous studies (34, 63), mixtures of vitronectin
with latent, inactive PAI-1 did not result in formation of any
complexes (data not shown).
Another PAI-1 mutant tested in these experiments was the
noninhibitory mutant PAI-1R (42). This double arginine mutant (T333R and A335R) is impaired in its ability to act as an
inhibitor of either tissue- or urokinase-type plasminogen activator due to the introduction of charges into strategic positions in the reactive center loop that impede the insertion of
this reactive center loop into the central ␤-sheet of the protein upon cleavage by plasminogen activators (42). However,
this mutant PAI-1 retains the ability to bind vitronectin. The
structural changes result in PAI-1R acting as a substrate, not
an inhibitor, for plasminogen activators; as such, this mutant
serves as a valuable tool for studying a variety of nonproteo-
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FIG. 6. Model for formation of higher order PAI-1-vitronectin complexes via the 2:1 intermediate. In this model, PAI-1 binds to
vitronectin in a concentration-dependent fashion to form the intermediate 1:1 and 2:1 PAI-1-vitronectin complexes. A conformational change
indicated by the species marked with an asterisk is proposed to occur uniquely in the 2:1 complex. This conformational change producing “altered”
vitronectin promotes oligomerization, leading to the assembly of the 4:2 PAI-1-vitronectin complex and additional higher order complexes. Free
PAI-1 also converts at a slow rate to a latent form, which cannot associate with vitronectin. This structural conversion over time leads to
accumulation of latent PAI-1, along with higher order vitronectin oligomers.

lytic roles of PAI-1 that are important during processes like
cell migration and tissue remodeling (32, 33, 64, 65). As
summarized in Table II, PAI-1R induces a similar formation
of higher order species as wild-type PAI-1. These findings
indicate that the ability of PAI-1 to promote the formation of
higher order complexes with vitronectin is independent of its
ability to inhibit plasminogen activators.
DISCUSSION

PAI-1 is an acute phase reactant that increases in concentration rapidly and locally in response to tissue damage, inflammation, and cancer (66). Large increases in PAI-1 concentration occur in cancerous (66, 67) and in wounded tissues (66,
68, 69). Indeed, plasma concentrations of PAI-1 in cancer patients have been shown to approach micromolar concentrations
(70), and high levels of PAI-1 are associated clinically with poor
outcome and survival (66, 67, 70). Our hypothesis is that PAI1-vitronectin complexes form by sequential occupation of two
PAI-1-binding sites on vitronectin, with occupation of the high
affinity site (Kd ⬃1–10 nM) under normal conditions at which
PAI-1 circulates in approximately nanomolar concentrations.
Occupation of the lower affinity site (Kd ⬃25–50 nM (34)3)
should occur in pathological situations with elevated PAI-1
concentrations that approach the dissociation constant for the
second site, a value ⬃10-fold weaker than that exhibited by the
primary binding site housed within the SMB domain. Furthermore, we suggest that the 2:1 PAI-1-vitronectin complex, which
is only formed at higher PAI-1 concentrations, is the key intermediate that regulates formation of the higher order adhesive
forms. We propose that the formation of these complexes in the
pericellular environment, with their concomitant targeting to
the ECM, accounts for the co-localization of PAI-1 and vitronectin that is observed in damaged and diseased tissues
(2, 18 –23).
The objective of this work was to evaluate this stepwise
assembly of PAI-1-vitronectin complexes in a concentration-dependent fashion via the 2:1 intermediate using SV analysis. By
selectively labeling each of the two reactant proteins, the optical capabilities of the analytical ultracentrifuge can be exploited so that discrete assignments of the composition and
stoichiometry of complexes is feasible. Moreover, a newly developed analytical method, multisignal analysis of SV data by
global analysis of c(s) distributions in the program SEDPHAT

(52), makes the quantitative aspects of this work more reliable.
Experiments were designed to analyze the distribution of oligomeric species that evolve when monomeric forms of PAI-1
and vitronectin are mixed under a variety of conditions and
protein concentrations. The novel method using SEPHAT was
instrumental in determining the molar ratios of PAI-1 and
vitronectin to conclusively demonstrate formation of the key
2:1 (PAI-1/vitronectin) regulatory intermediate under conditions in which higher order complexes are produced.
A scheme based on the SV analysis summarizes a proposed
mechanism for assembly of PAI-1-vitronectin complexes (Fig.
6). Evaluation of the dose-dependent effects of PAI-1 show that
in the first assembly step, PAI-1 binds with vitronectin to form
a complex at 5.5 S, which consists of a single molecule of PAI-1
bound to a high affinity binding site on vitronectin (Table I, Fig.
6). As PAI-1 levels are increased, occupation of the second,
relatively lower affinity binding site on vitronectin leads to the
formation of the 6.5 S (2:1) species. The crucial 2:1 complex
promotes oligomerization, serving as a building block for assembly of higher order complexes. Once this 6.5 S species
accumulates, higher order complexes are produced, with a
broad distribution in s values ranging from 7.5 to 25 S. In
agreement with an earlier study using sedimentation equilibrium analysis (37), the new results demonstrate the formation
of a dominant oligomeric species with a 4:2 PAI-1/vitronectin
molar stoichiometry that exhibits sedimentation coefficients of
⬃8 –10 S (Table I).
What are the structural requirements for assembly of these
higher order forms? Experiments with mutant forms of PAI-1
indicate the inherent rate of conversion of PAI-1 to a latent
conformation has a relatively minimal effect on whether or not
the higher order complexes are formed. However, there are
some differences when comparing our other work on SV analyses of the 14-1B PAI-1 mutant2 with the observations here on
the W175F “stable” PAI-1 mutant. The well characterized
14-1B mutant of PAI-1 is another “stable” PAI-1 mutant that
converts more slowly to the latent form. It contains four mutations, three of which are found within the central ␤-sheet core
(40). The SV analyses showed that fewer higher order complexes with s values greater than 15 S are formed with the
14-1B isoform than with W175F PAI-1, given comparable conditions. Other recent observations substantiate differences be-
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tween these two “stable” forms of PAI-1, including a report that
14-1B-PAI-1 shows reduced activity against tPA and thrombin
under certain experimental conditions (71). Also, structural
work using fluorescence resonance energy transfer indicates
that 14-1B and wild-type PAI-1 differ in the orientation of the
reactive center loop, with the loop of wild-type PAI-1 being
folded in closer proximity to the protein core and partially
inserted (72). Consistently, the frictional ratio from the SV
work on 14-1B-PAI-1 is 1.4, indicative of a larger hydrodynamic
radius compared with the f/f0 of 1.2 for wild-type PAI-1, W175F
PAI-1, and PAI-1R (data not shown). Nevertheless, it is clear
from the work on these stable PAI-1 proteins that their ability
to foster formation of the higher order vitronectin complexes is
independent of the rate at which the serpin converts to a latent
form.
Behavior of another mutant form of PAI-1 in this study,
PAI-1R, also demonstrates that an active serpin inhibitor is not
required to promote the accumulation of higher order oligomers. In fact, the noninhibitory PAI-1R protein merely acts
as a substrate for proteases, and cleaved PAI-1R product does
not undergo insertion of the cleaved reactive center loop into
the central ␤-sheet (42). From the analyses on these mutant
forms of PAI-1, it appears that the binding of PAI-1 to vitronectin leads to the higher order complexes, irrespective of whether
␤-sheet rearrangements in PAI-1 ensue. However, as suggested
in our model in Fig. 6, binding in itself is presumably not
sufficient to produce these higher order complexes. Instead, we
propose that a conformational change occurs in vitronectin
within the 2:1 complex, leading to the higher order complexes
containing the “altered” form of vitronectin that adopts an
adhesive role.
What support is there for this proposed conformational
change in vitronectin that favors its association to the higher
order forms? Evidence for a structurally altered form of
vitronectin comes from studies using monoclonal antibodies to
demonstrate conformational differences in the native and altered (“activated”) forms of vitronectin that become tissueassociated in pathological settings (3, 73, 74). Also relevant is
work by Seiffert and Smith (75, 76) that suggests that ligandbinding sites housed in the SMB domain are cryptic in the
native structure of vitronectin but become more exposed upon
interaction of ligands with the heparin-binding site near the C
terminus of the protein. Consistent with this idea, we have
shown that the higher order PAI-1-vitronectin complexes that
exhibited altered binding to receptors also localize to the ECM
via interactions with glycosaminoglycans.2 Furthermore, our
prior work on denaturation and renaturation of vitronectin
demonstrated that the conformational change to an “altered” or
“activated” form in vitronectin is irreversible, since native,
monomeric protein was never recovered from the altered structure of vitronectin generated from such experiments (39, 77).
In conclusion, we have utilized SV analysis to elaborate on
the mechanism that regulates the assembly of PAI-1-vitronectin complexes. Here, we show that PAI-1, via stepwise formation of intermediates in a concentration-dependent manner,
forms a 2:1 complex that regulates the formation of higher
order PAI-1-vitronectin complexes. This process of assembly of
higher order complexes that are relocalized to the ECM provides a molecular mechanism for depositing PAI-1 and
vitronectin into the pericellular space of tissues, where functional properties of both proteins become locally manifested.
These findings should provide insight into the observed dependence of processes like tumor growth and angiogenesis on
local levels of PAI-1 (78, 79).
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